$CBIS to Be a Featured Guest on “Your Money’s Worth” National Radio Show

Cannabis Science, Inc. (OTC PINK:CBIS), a U.S. company specializing in the development of cannabis-based medicines, will be a featured guest tonight on “Your Money’s Worth,” a long-running radio show hosted by business and sports broadcaster, Mick “The Mixter” Bazsuly. The radio show will air from 5:00pm to 7:00pm EST tonight, and can be heard on 1470AM WWNN, South Florida or live streaming on www.wwnnradio.com &www.amp2.tv.

“We are focusing this particular show on the cannabis industry, both from the explosive growth of this industry and the legalization for medical usage as well as recreational use in America,” said Bazsuly. “The benefits of cannabis use for the treatment of some diseases cannot be contested.”

CEO Raymond C. Dabney will speak to the company’s progress over the past year as well as the overall strategy and goals for the upcoming year. This will include discussion on drug development, the growing management team, corporate initiatives, and ongoing research. The direct studio phone line will be available for investors and the general public to call in to ask their questions live.

The phone number to reach the studio is 1-888-565-1470. Callers with questions are encouraged to call in between 5:00pm and 7:00pm EST to ask their questions. The show can be heard live on 1470AM, WWNN in Southern Florida or online at www.wwnnradio.com as well aswww.amp2.tv

“We are excited to have the opportunity to speak with everyone, answer their questions directly, and share what we have been working so diligently on for the past year,” said Dabney.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.